STOCK TITAN

Taysha Gene Therapies Inc - TSHA STOCK NEWS

Welcome to our dedicated news page for Taysha Gene Therapies (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Taysha Gene Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Taysha Gene Therapies's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
97.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
97.35%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.06%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.52%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.22%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
conferences
Taysha Gene Therapies Inc

Nasdaq:TSHA

TSHA Rankings

TSHA Stock Data

592.85M
100.06M
24.77%
69.75%
7.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Dallas

About TSHA

taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.